Life Sciences Ontario
Annual Report 2022
1. MESSAGES
Message from the Chair & CEO ............................................................................................................................2

2. YEAR IN REVIEW
LSO’s Impact in 2022 ................................................................................................................................................3
Policy and Government Relations ............................................................................................................................4
Queen’s Park Day ....................................................................................................................................................6
Business Development and Member Engagement ..................................................................................................7
Scholarship Program .............................................................................................................................................8
Ideas to Action Forum ..........................................................................................................................................9
Annual Awards Presentation .................................................................................................................................10
Knowledge & Networking Breakfasts/Webinars ....................................................................................................11
Annual Golf Classic .............................................................................................................................................12

3. ABOUT LSO
About LSO .............................................................................................................................................................13
Board of Directors ...............................................................................................................................................14
Members and Partners .......................................................................................................................................15
Thank You to Our Corporate Sponsors ...............................................................................................................16
Committee Members ...........................................................................................................................................17
Thank You to Our Event Sponsors ......................................................................................................................18

LAND ACKNOWLEDGEMENT
LSO acknowledges that we are on the traditional territory of many nations including the Mississaugas of the Credit, the Anishnabeg, the Chippewa, the Haudenosaunee and the Wendat peoples and is now home to many diverse First Nations, Inuit and Métis peoples. LSO also acknowledges that Ontario is covered by Treaty 13 signed with the Mississaugas of the Credit, and the Williams Treaties signed with multiple Mississaugas and Chippewa bands.
Message from the Chair and President & CEO

2022 has been a year of recovery and advancement for Ontario's Life Sciences sector. The COVID19 pandemic proved challenging for many businesses; but it also brought awareness and recognition as to the value of life sciences and the innovations that carried us through this crisis.

As we emerge from the COVID19 Pandemic, LSO was once again able to host our annual events in-person, including our Awards Celebration and our Ideas to Action Life Sciences Forum. The energy and excitement at these events have been overwhelming as our members trade the pajama pants for business attire and transition back to networking with friends and colleagues.

For the past decade, long before COVID19, LSO has advocated for the need for a provincial life sciences strategy. During that time, we’ve developed several reports, roadmaps and blueprints that detail the elements that should form the strategy and that quantify the significant return on investing in life sciences. In March 2022, the Ontario government announced “Taking life sciences to the next level – Ontario’s strategy”. This was the culmination of a decade of advocacy from LSO, our members and our partners across life sciences and is a milestone for the sector. But our work is not done.

Strategies are only effective if implemented. In particular, Ontario’s strategy has called for the formation of a forward-looking life sciences council that will focus on long-term growth and competitiveness in four key subsectors: medical technology, pharma/biotech, digital health, and personal protective equipment. To date, this council has yet to be established and is a critical component to ensure that this strategy is not just another one-off announcement but rather the start of a life sciences revolution for Ontario.

Finally, we are continuing our work on key priority areas such as the call for a provincial rare disease strategy, support for innovation and building an inclusive life sciences future through the principles of IDEA (Inclusion, Diversity, Equity and Accessibility). With the help of our members, partners and supporters, and with the same determined advocacy, we will see success in these areas as well. 2023 will be an exciting year for life sciences in Ontario and we look forward to continuing our work with all of you – our valued life sciences community.

Mark Smithyes
Chair, LSO Board of Directors

“LSO will continue to work with our partners to hold the government accountable to translating this strategy into action.”

Jason Field
President & CEO, Life Sciences Ontario
LSO’s Impact in 2022

Connecting the Life Sciences Sector

2843 Connections

143 for the Annual Policy Forum
171 Golf Classic Attendees
403 Awards Presentation Attendees
2126 registrants for our virtual webinars

INCREASING ONLINE VISIBILITY
Of our members and our sector

15,000+ Social Media Follows
Web Page Views: 78,268 views
Website Visits: 36,945 visits

IMPACT OF LSO SCHOLARSHIP PROGRAM
Results of students surveyed in the first 3 years of the program

84% said the LSO Scholarship Program helped achieve their goals
90% of applicants went on to graduate studies
75% agreed that the Scholarship Program contributed to their success

STRENGTHENING THE SECTOR ACROSS THE PROVINCE

<table>
<thead>
<tr>
<th>Institution</th>
<th># of Scholarships Awarded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brock University</td>
<td>3</td>
</tr>
<tr>
<td>Carleton University</td>
<td>2</td>
</tr>
<tr>
<td>Laurentian University</td>
<td>2</td>
</tr>
<tr>
<td>McMaster University</td>
<td>40</td>
</tr>
<tr>
<td>Ontario Tech University</td>
<td>1</td>
</tr>
<tr>
<td>Queen’s University</td>
<td>12</td>
</tr>
<tr>
<td>Toronto Metropolitan University</td>
<td>5</td>
</tr>
<tr>
<td>University of Guelph</td>
<td>12</td>
</tr>
<tr>
<td>University of Ottawa</td>
<td>11</td>
</tr>
<tr>
<td>University of Toronto</td>
<td>22</td>
</tr>
<tr>
<td>University of Waterloo</td>
<td>12</td>
</tr>
<tr>
<td>Western University</td>
<td>11</td>
</tr>
<tr>
<td>York University</td>
<td>2</td>
</tr>
</tbody>
</table>
This year, LSO continued our advocacy efforts in support of a strong, resilient, and diverse life sciences sector. In February 2022, LSO submitted our pre-budget submission to Finance Canada ahead of Budget 2022. We asked the federal government to implement the Biomanufacturing and Life Sciences Strategy (BLSS) (see here: http://bit.ly/3kQZFTQ), establish an advisory team consisting of private and public stakeholders in the life sciences to guide the implementation of the BLSS, and repeal proposed changes to the Patented Medicine Prices Review Board (PMPRB) guidelines. Please read our full submission here: https://bit.ly/3ITzhki. In February, LSO also provided its submission for the Canadian Agency for Drugs and Technologies in Health’s (CADTH) consultation on a pan-Canadian national formulary. Please see our submission here: https://bit.ly/3moGj8V.

On World Rare Disease Day, February 28th, LSO along with the Canadian Organization for Rare Disorders (CORD) convened a roundtable with leading Ontario legislators and health policy experts to discuss how a provincial rare disease strategy can help save lives and boost our economy. The roundtable built upon LSO’s previous advocacy work in rare disease, including our report, Cast Our Pebble Into the Pond, which you can read here: https://bit.ly/3IT68Wq.

In March 2022, LSO was pleased to welcome the announcement of Ontario’s Life Sciences Strategy, Taking Life Sciences to the Next Level, which you can read here: http://bit.ly/3kS3isG. The strategy promises to transform Ontario to a leading life sciences hub by 2030 by focusing on 4 key goals:

1) growing Ontario’s biomanufacturing output;
2) improving domestic supply of PPE and critical medical supplies;
3) strengthening commercialization capacity of Ontario companies and SMEs and
4) adopting made-in-Ontario innovations into our health system.

The announcement followed years of advocacy on behalf of LSO and its partners for a coordinated life sciences strategy, including LSO’s report, Blueprint for a Coordinated Ontario Life Sciences Strategy, which can be read here: https://bit.ly/3kQXKi8. To read our press release following the announcement, kindly visit: http://bit.ly/3ZIHEpz.
Last year, LSO commissioned IQVIA to conduct research on Canada’s global position as a launch country for new medicines. The research found that the number of new medicines launched in Canada has steadily declined since 2016. This finding is the opposite of recent global trends for new medicine launches based on sales from the top 25 countries in 2021. To read the complete findings from this research, please visit: https://bit.ly/3L5sarL.

In June, we attended BIO2022 as part of the Canadian Pavilion. It was great connecting with colleagues from Ontario, Canada, and from around the world to share the benefits of Ontario’s Life Sciences.

In 2022, LSO continued our advocacy efforts regarding proposed changes to the Patented Medicine Prices Review Board’s (PMPRB) guidelines. LSO has advocated for changes to the proposed PMPRB guidelines that are guided by clarity, transparency, certainty, and fairness. In July 2022, LSO provided our recommendations in response to the PMPRB’s proposed guidelines. We recommended that the PMPRB consider the following:

1) establish working groups and review case studies;
2) operate within the PMPRB’s clarified mandate to regulate patent abuse;
3) align with broader government priorities, including the Biomanufacturing and Life Sciences Strategy and
4) introduce grandfathering on-market medicines.

To read our full submission: https://bit.ly/3ymjNQF.

In December, LSO collaborated with Montréal InVivo to submit our recommendations in response to the PMPRB’s proposed guidelines. Our recommendations called for an immediate pause to the PMPRB’s proposed guidelines to allow more time for analysis, case studies, and dialogue with stakeholders. The PMPRB paused the implementation of these guidelines in January 2023. To read our joint submission, please visit: https://bit.ly/3YnRImW.

LSO held our Ideas to Action Forum, formerly known as our annual policy forum, in November. The forum brought together stakeholders and leaders from across the life sciences sector to discuss how we can take actionable steps to empower the life sciences in both Ontario and Canada. For the first time since 2019, we were pleased to host this year’s event in-person, which featured panelists from government, industry, and academia. Across five panels, we explored topics such as talent, data, and infrastructure in the life sciences, and also strategized how to coordinate life sciences strategies across jurisdictions in Canada. The outcomes from our Ideas To Action forum will help shape LSO’s advocacy for the new year and beyond. You can view our full outcomes report from the forum here: https://rb.gy/jdbgpf. We also have a short summary available here: https://rb.gy/fpuvpi.

Following our advocacy work with C.A.R.P. in 2021, LSO continued the “Aim Higher” campaign, which looks at how Canada can improve its standing among global health systems. The campaign, which is featured in a 2-page spread in Zoomer magazine, proposes a 3-point plan:

1) focus on results that matter to patients;
2) cut unnecessary red tape and
3) invest wisely.
Queen’s Park Day

Every year, LSO hosts our Queen’s Park Day, which brings together industry leaders and stakeholders from across the life science sector with policymakers in the Ontario government to discuss how we can build a vibrant life sciences sector that will support our economic growth, strengthen the capacity of our health care system, and boost our global competitiveness. LSO and our members met with a total of 23 members of the provincial parliament (MPPs) during our hybrid event and shared our three recommendations for building a strong life sciences sector:

1) implement the Ontario Life Sciences Strategy, including the Life Sciences Council;
2) promote Ontario as a national leader in the life sciences, including support for and adoption of made-in-Canada innovations, and
3) develop a provincial rare disease strategy.

On November 23rd, we held our in-person Queen’s Park Day reception. MPPs from the three major provincial parties delivered remarks on the importance of Ontario’s life sciences sector. Speakers included Nina Tangri (MPP from Mississauga-Streetsville), Catherine Fife (MPP from Waterloo), and John Fraser (MPP from Ottawa South).

To coincide with our Queen’s Park Day, we also released our 2022 Success Stories, which feature the recent work and accomplishments of our members organizations. You can learn how our member organizations are tackling challenges and empowering Ontario’s life sciences sector with new innovations here: https://rb.gy/bl9qsx.
“We’ve been everywhere man...we’ve been everywhere.” As the Man in Black, Johnny Cash, once crooned, this is how 2022 could be summed up for Life Sciences Ontario’s business development and member engagement efforts. In support of our mission of fostering a commercially successful life sciences sector in Ontario and beyond, we have touched down in several major markets where life sciences is thriving as an ecosystem. We are expanding our footprint across the province and throughout the sector in innumerable ways: from attending international conferences such as BIO in San Diego or Medtech Conference in Boston; to exploring the various markets where life sciences is flourishing to identify organizations with a link, interest and ability to invest in our services. We are doing it all!

We have focused our efforts on working with life sciences companies, services providers or institutions acting as incubators for commercialization and scaling organizations or with regional institutions charged with amplifying those within their regional borders in the life sciences ecosystems. Life Sciences Ontario has offered each region of the province an opportunity to amplify and connect to their specific audiences. These efforts translated into 38 additional companies joining the Association, which allowed us to increase overall membership revenues from 2021 by 2%. In several instances, we have secured multi-year memberships from various institutions working with us to enhance awareness of life sciences in their respective markets.

The second area of impact has been within Member Engagement, where we are working on the premise of building and nurturing long-term and mutually beneficial opportunities, in support of corporate investments through both human and financial capital. By identifying various levels of engagement within the organization, we have far exceeded initial projections by securing significant financial revenues and increasing overall sponsorships by 20% from 2021. This allowed us to see 2022 as a defining moment in how our members, both new and existing, have seen the value of their association with LSO.

Finally, by encouraging, amplifying and connecting our membership to the life sciences ecosystems here beyond our provincial borders via marketing vehicles such as our newsletter, social media and networking events, we continue to provide value to our members by enhancing both brand awareness and audience engagement. By creating a two-way relationship and encouraging deeper investments such as participating on crucial volunteer committees, we continue to see incredible opportunities for future collaboration. As we look towards 2023, our team strongly believes that through a coordinated and collaborative approach, every win for life sciences will ultimately translate into a win for us all.
Scholarship Program

The Life Sciences Ontario (LSO) Scholarship and Mentorship program was developed in 2019 and has grown from its modest beginnings to becoming an important element of the LSO mandate, under education and mentorship. In the 4 years of running the program, we have provided financial support to 135 students worth $425,000. And more importantly, we have paired each student up with an experienced professional within the life sciences sector. Through the support of our sponsors over the years, we have been able to help bring awareness to the many opportunities that exist in Ontario’s life sciences sector. The 2022 Scholarship and Mentorship was made possible thanks to the generous support of our sponsors:

The Life Sciences Ontario Scholarship Program is an excellent opportunity for students in Life Sciences to connect with many influential individuals in this field. This program has opened my eyes to unique career pathways and provided me with many insights on how to excel in this industry. Overall, this program is a great gateway into the Life Sciences industry and I would recommend it to all students in this field.

- Simonne Rauch, Queen's University 2022 Award Recipient

HOW THE LSO SCHOLARSHIP PROGRAM HELPS ADDRESS DIVERSITY AND TALENT SHORTAGES IN THE LIFE SCIENCES

The Problem

Biotalent Canada’s report “Close-up on the bio-economy – National Report” predicts the demand for talent in all sectors of Canada’s bio-economy will far exceed the supply of available brainpower by as soon as 2024. And if that happens, progress will slow, growth will stall.

By 2029 the Life Sciences Sector will have an additional 65,000 jobs and not enough people to fill those jobs.

A look at the Sector today:

women make up only 34% of the workforce

only 20% of the workforce are visible minorities

Contributing To The Solution

The LSO Scholarship Program provides not only financial support for the next generation of life sciences employees but also a mentorship component connecting them with leaders to explore the different careers and opportunities within the sector.

In the 2022 Scholarship Awards:

- 66% of applicants identified as women
- 72% of scholarships were awarded to applicants identified as women
- 65% of applicants that identified as visible minorities
- 70% of scholarships were awarded to applicants that identified as visible minorities

Over the last 4 years we have awarded 135 scholarships worth $425,000

Program Sponsors

Alexion
Gilead
Horizon
Novo Nordisk
AstraZeneca
Roche
Sanofi
Takeda
Boehringer Ingelheim
360 Public Affairs
CSL Behring
Jazz Pharmaceuticals
Our 2022 Ideas to Action Forum (formerly, the Policy Forum), which was held on November 3rd 2022, brought together stakeholders and leaders from across the life sciences sector to discuss how we can take actionable steps to empower the life sciences in both Ontario and Canada. A resilient and vibrant life sciences sector can help solve many of the challenges Ontario currently faces, including health system capacity, economic recovery, sustainability, and pandemic preparedness. The goal of this forum is to explore how we can move from discussion to real action that will impact our sector.

This year’s event had 160 attendees. Across our five panel sessions, we asked 25 leaders representing industry, academia, and government to prepare an action item related to their panel’s topic. We established the top action item from each of our panels as voted on by the audience. These actions items will shape Life Sciences Ontario’s advocacy efforts moving forward—for 2023 and beyond.

Some of the key outputs as a result from our 2022 Ideas to Action forum include:

- Expanding sciences strategies beyond governments to secure buy-in, leadership, and coordination from public and private sectors and all relevant stakeholders.
- Leveraging offerings across the sector and do not duplicate efforts—the government should work with all stakeholders to create a map of training and talent development offerings to guide learners and organizations.
- Investing more money in areas related to data infrastructure, platforms, and governance beyond a project specific basis.
- Creating an environment for rapid evaluation and adoption of health care technologies for Ontario’s health system.

Following the Policy Forum, we have created a summary report from the discussion. To read the full report, please visit: https://rb.gy/fpuvpi.
Celebrating our 19th year, LSO’s Annual Celebration of Success has formed a reputation as an important platform to recognize the individuals and companies driving the success of Ontario life sciences. The LSO Awards Presentation is our largest single fundraising vehicle—supporting our advocacy, educational, and networking events. The event also served an important charitable function: proceeds from the event’s silent auction support the Sanofi Biogenius Challenge. This year we were excited to host in-person at the Liberty Grand, which was a very successful event of much-needed networking after a 2-year hiatus due to the pandemic. And the best part was that there was no snow.

We would like to acknowledge our event sponsors and the outstanding efforts of the Awards Presentation Committee and its Co-Chairs, Jason Locklin and Jill Osborne; the Awards Review Chair, Beni Rovinski; and our dedicated volunteers and staff who help make this event a success.


The 2022 awardees were:

- **Lifetime Achievement Award:** Ronnie Miller, President & CEO, Hoffmann-La Roche Limited
- **Community Service Award:** Dr. Jack Gauldie, Distinguished University Professor, Department of Pathology and Molecular Medicine, McMaster University
- **Volunteer Award:** Dr. Ryan Wiley, President, Shift Health
- **Life Science Company of the Year:** Nicoya
  Ryan Denomme, CEO & Co-Founder
- **LSO Leadership Award:** Sabina Steinkellner, General Manager, General Medicines Canada, Sanofi
Knowledge & Networking Breakfast / Webinar Series

Life Sciences Ontario’s Knowledge and Breakfast Meetings are a long-standing tradition, with the first event being held in September 1989, when LSO was known as TBI (Toronto Biotechnology Initiative). The Committee has continued to capitalize on the ability to maximize the impact of our events through various virtual platforms. These platforms have enabled LSO to continue to provide dynamic and engaging educational content to the life sciences sector. The virtual landscape has allowed us to increase our reach in terms of both participants (we had a total of 2,126 registrants in 2022) and having speakers across the province and outside of Ontario and Canada.

This year’s topics included:

- Psychedelics for Medical Use (January 20th)
- Advancing Canadian Health Care Through Innovation Series Procuring Change: Advancing Canadian Innovation (February 1st)
- Beyond the lab coat: What could a career in life sciences, health, medical & agriculture industries looks like? (February 8th)
- Entrepreneurship in Action (February 17th)
- LSO AGM with Guest Speaker Brian Bloom (March 17th)
- Advances in Medical Technology (April 21st)
- New Frontiers in Food Innovation (May 10th)
- Lab Space: Opportunities in the Real Estate Market | Overview of the Construction Process and Costing (May 31st)
- LSO Member Marathon (June 21st)
- Summer of Sciences (July 21st)
- Virtual Roadtrip around the Province!
  » Sept 26th: Windsor
  » Sept 27th: Brampton
  » Sept 28th: London
  » Sept 29th: Simcoe County, Barrie, Orillia
  » Sept 30th: Ottawa
- Back to office – best practices managing in-person & virtual employees (October 20th)
- Cyber Security (Nov 24th)
- LSO Member Marathon (Dec 15th)

Visit our YouTube channel to view some of the recordings: [https://www.youtube.com/user/LifeSciencesON](https://www.youtube.com/user/LifeSciencesON)
Annual Golf Classic

Our 2022 Annual LSO Golf Classic was a resounding success and we had the perfect weather for this year’s event. We had 144 attendees, making it another sell out! As you may know, this event provides an important and engaging environment for the life sciences community, and most importantly, supports Sanofi Biogenius Canada through our silent auction. This year, through our silent auction, we were able to raise $3,415 and our hole-sponsor, BioBenefits, raised an additional $2,070 for a total of $5,485 to support Sanofi Biogenius Canada!

Of course, this beloved event would not be possible without our generous event sponsors and thoughtful event donors. The LSO team, the LSO Board, and the LSO Golf Committee would like to shout out a huge thank you to the following:

EVENT SPONSORS

EVENT DONORS
3Sixty, AGO, Cano, Casa Loma, Clarivate, Cleveland Golf, Fieldgate, Hugh Wood Canada Insurance, Konzelmann, Marsh, Metro Golf Sportplex, LCBO, Liberty Grand Group, Longo’s, Niagara Canada, Peak Pharma Solutions, PharmEng Technology, Pillitteri Estates Winery, Steam Whistle, Troutman Pepper, and ValGenesis.

At the event, we had some great games and prizes, including guessing the correct numeric combination to open a vault for a chance to win $50,000! For next year, we are aiming for an even bigger turnout with more activities and prizes. As always, we are grateful for all our Committee Members for their unwavering support, guidance and leadership.
LSO is a business-led, member-funded, not-for-profit organization with a legacy of more than 30 years advancing the success of Ontario’s life sciences sector. Our customized approach to working with member companies and industry partners allows us to leverage the strengths of the LSO network to commercialize Canadian innovation and technologies, while offering value-added support, services, mentorship, and events.

Mission
LSO’s mission is to foster commercial success for the sector through advocacy and education, and promoting the industry locally, nationally, and internationally.

Values
- Consultation and collaboration
- Inclusivity and consensus-building
- An aligned voice on key policy matters
- A hub-based approach
- Evidence based decision making
- The equal social and economic benefits of life sciences

Strategic Priorities
1. Raising the profile of Ontario’s Life Sciences sector to secure our economic and social prosperity.

2. Advocating for specific public policy action to support our sector’s continued growth, such as access to capital, an inclusive and aligned provincial life sciences strategy, and evidence-based decision-making.

3. Delivering unparalleled educational, networking, mentorship, and thought leadership programs to our members.

4. Acting as a centralized hub connecting our sector’s diverse clusters to facilitate a strong, aligned life sciences sector with national connectivity.
Board of Directors

Executive Committee

Mark Smithyes
Chair

Alison Symington
Vice Chair
Principal, Life Science Strategic Consulting

Rafi Hofstein
Member of the Executive former President and CEO, Toronto Innovation Acceleration Partners

Susan Marlin
Member of the Executive President & CEO, Clinical Trials Ontario

Bronwynne Wilton
Member of the Executive Principal and Lead Consultant, Wilton Consulting Group

Anne Woods
Member of the Executive Managing Director, Life Science & Healthcare, Silicon Valley Bank

Officers

Laura Sluce
Treasurer
Partner, Ernst & Young LLP

Nicole DeKort
President & CEO, Medtech Canada

Lauren Fischer
Lead, Government Affairs, AbbVie Canada

Ingrid Fung
Investment Director Toronto, Finistere Ventures

Jeff Graham
Senior Vice President, Head of Legal & Regulatory Compliance, Skypower Global

John Haslam
General Manager, Argenx

Manoj Pundit
Secretary
Partner, Borden Ladner Gervais LLP

Jason Locklin
Director, Market Access, Policy & Government Relations, Argenx

Andrea Palmer
CEO and Founder, Awake Labs

Benjamin Rovinski
Managing Director, Lumira Ventures

Alexis Sciuk
Canadian Health Care Solutions, Lead, Pfizer Canada Inc

Sabina Steinhellner
General Manager, General Medicines Canada, Sanofi Canada

Directors

Emily Titus
Vice President, Process Sciences, Notch Therapeutics

Bernard West
President, Westworks Consulting Limited

John Wilkinson
Board Member, Greenfield Global

Russell Williams
Senior Vice President, Mission, Diabetes Canada
Thank You to Our Corporate Sponsors

**Platinum**

ALEXION  
astellas  
HORIZON

INNOVATIVE MEDICINES CANADA  
Roche  
sanofi

Shift HEALTH  
svb Silicon Valley Bank

**Gold**

adMare BIOTECHNOLOGIES  
BD  
BioTalent Canada  
stryker  
TAIHO PHARMA CANADA, INC.

**Silver**

BDO  
EY  
NIAGARA CANADA

AmerisourceBergen  
CRB  
UNIVERSITY OF TORONTO SCARBOROUGH
LSO would like to thank our Board of Directors, many volunteer members and partners, for their contributions to LSO in 2022.

Executive Committee
Mark Smithyes (Chair)
Alison Symington (Vice Chair)
Susan Marlin
Rafi Hofstein
Bronwynne Wilton
Anne Woods

Awards Presentation Committee
Jason Locklin (Presentation Co-Chair)
Jill Osborne (Presentation Co-Chair)
Benjamin Rovinski (Review Chair)
Shelley Almeida
Luis Barreto
Murray McLaughlin
Magda O’Sullivan
Kira Pejemskey
Alison Symington
Bronwynne Wilton
Anne Woods

Ideas to Action Committee
Ryan Wiley (Chair)
Mike Foorer
Ingrid Fung
Jeffrey Graham
Sean McBride
Ana McGovern
Anne Mullin
Eric Pegolo
Andrew Retfalvi
Benjamin Rovinski
Mark Smithyes

Knowledge and Networking Breakfast Committee
Alison Symington (Chair)
Jamie Barron
Chris Delvecchio
Jodi Garner
Danny Ladouceur
Carolyn Lee
Vanessa Williamson
Anne Woods

Golf Committee
John Gouday (Co-Chair)
Esther Wiltshire (Co-Chair)
Ken Feinstein
Will Gehrng
Daniel Lacey
Bruno Maruzzo
Jackie O’Connor

Policy and Government Relations
Rupinder Bagha
Susan Baker
Suchandra Banerjee
Diane Bigras
Shanna Brisebois
Matthew Bureau
Logan Caragata
Ryan Clarke
Dana Corsen
Doug Daniel
Emanuela De Franco
Phil Delistoyanov
William Dempster
Stephanie Dunlop
Patrick Faubert
Jeff Graham
Laura Greer
Grant Gunn
John Haslam
Ken Hughes
Farah Jivraj
Pamela Kanellis
RJ Kayser
Adrian Kupesic
Matt Lee
Colin LeFevre
Jason Locklin
Rob Loney
Susan MacLean
Sean McBride
Pamela McDonald Kuhn
Scott Mulligan
Forrest Parlee
Eric Pegolo
Marko Perovic
Anie Perrault
Hugues Poulin
Christopher Praught
Laurene Redding
Andrew Retfalvi
Sarah Shephard
Chelsea Smallwood
Mark Smithyes
Michael Stamper
Amy Swanson
Gurman Virk
Bernard West
Kathleen Whelan
John Wilkinson
Nadia Yee
Howard Zach

Inclusion, Diversity, Equity and Accessibility (IDEA) Committee
Sabina Steinkellner (Chair)
Wanda Deschamps
Laleh Moshiri
Andrea Palmer
Manoj Pundit
Mark Smithyes
Thank You to Our Event Sponsors
INDEX

Page  1-2.  Independent Auditor's Report

3.  Statement of Financial Position


5.  Statement of Cash Flows

6-9.  Notes to Financial Statements
INDEPENDENT AUDITOR’S REPORT

To the Members and Board of Directors
Life Sciences Ontario
TORONTO
Ontario

Opinion
We have audited the accompanying financial statements of Life Sciences Ontario which comprise the statement of financial position as at December 31, 2022 and the statement of operations and changes in net assets and statement of cash flows for the year then ended and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the entity as at December 31, 2022 and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Opinion
We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the entity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the entity’s financial reporting process.

Auditor’s Responsibilities for the Audit of the Financial Statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the entity to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

NORTON McMULLEN LLP
Chartered Professional Accountants, Licensed Public Accountants

MARKHAM, Canada
February 7, 2023
# Statement of Financial Position

As at December 31, 2022

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current</strong></td>
<td>$1,047,867</td>
<td>$1,029,382</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,047,867</td>
<td>$1,029,382</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>2,921</td>
<td>1,875</td>
</tr>
<tr>
<td>HST refundable</td>
<td>125,336</td>
<td>61,741</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>56,627</td>
<td>25,804</td>
</tr>
<tr>
<td><strong>Capital Assets (Note 2)</strong></td>
<td>4,124</td>
<td>3,689</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$1,232,751</td>
<td>$1,118,802</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current</strong></td>
<td>$419,161</td>
<td>$404,795</td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$187,234</td>
<td>$72,740</td>
</tr>
<tr>
<td>Deferred revenue (Note 3)</td>
<td>231,927</td>
<td>332,055</td>
</tr>
<tr>
<td><strong>CEBA Loan (Note 4)</strong></td>
<td>40,000</td>
<td>40,000</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>$459,161</td>
<td>$444,795</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NET ASSETS</strong></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>$777,714</td>
<td>677,696</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Commitment (Note 5)</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>$1,236,875</td>
<td>$1,122,491</td>
</tr>
</tbody>
</table>

Approved by the Board:

Director

Director

See accompanying notes
## Statement of Operations and Changes in Net Assets

For the year ended December 31, 2022

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special projects</td>
<td>$916,716</td>
<td>$953,413</td>
</tr>
<tr>
<td>Membership and general sponsorship</td>
<td>477,642</td>
<td>442,360</td>
</tr>
<tr>
<td>Events and meetings</td>
<td>471,720</td>
<td>310,534</td>
</tr>
<tr>
<td>Education programs</td>
<td>156,235</td>
<td>180,324</td>
</tr>
<tr>
<td>Government assistance</td>
<td>-</td>
<td>117,214</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td>$2,022,313</td>
<td>$2,003,845</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special projects</td>
<td>$825,238</td>
<td>$858,757</td>
</tr>
<tr>
<td>Office and general</td>
<td>756,556</td>
<td>629,845</td>
</tr>
<tr>
<td>Events and meetings</td>
<td>198,011</td>
<td>89,642</td>
</tr>
<tr>
<td>Education programs</td>
<td>122,053</td>
<td>148,301</td>
</tr>
<tr>
<td>Bank charges</td>
<td>9,844</td>
<td>8,366</td>
</tr>
<tr>
<td>Communications</td>
<td>9,385</td>
<td>1,733</td>
</tr>
<tr>
<td>Amortization</td>
<td>1,208</td>
<td>1,322</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$1,922,295</td>
<td>$1,737,966</td>
</tr>
<tr>
<td><strong>Excess of Revenues Over Expenses</strong></td>
<td>$100,018</td>
<td>$265,879</td>
</tr>
<tr>
<td><strong>Net Assets - Beginning</strong></td>
<td>$677,696</td>
<td>$411,817</td>
</tr>
<tr>
<td><strong>Net Assets - Ending</strong></td>
<td>$777,714</td>
<td>$677,696</td>
</tr>
</tbody>
</table>

See accompanying notes - 4 -
LIFE SCIENCES ONTARIO

STATEMENT OF CASH FLOWS

For the year ended December 31, 2022

CASH AND CASH EQUIVALENTS WERE PROVIDED BY (USED IN):

OPERATING ACTIVITIES
Excess of revenues over expenses $100,018 $265,879

Items not affecting cash and cash equivalents:
   Amortization 1,208 1,322
   Forgivable portion of CEBA loan - (10,000)

$101,226 $257,201

Net change in non-cash working capital balances:
   Accounts receivable (1,046) 125
   HST refundable (63,595) (72,981)
   Prepaid expenses (30,823) 70,427
   Accounts payable and accrued liabilities 114,494 22,075
   Deferred revenue (100,128) 104,110

$20,128 $380,957

INVESTING ACTIVITIES
   Purchases of capital assets (1,643) -

FINANCING ACTIVITIES
   Proceeds from CEBA loan - 20,000

INCREASE IN CASH AND CASH EQUIVALENTS $18,485 $400,957

CASH AND CASH EQUIVALENTS - Beginning 1,029,382 628,425

CASH AND CASH EQUIVALENTS - Ending $1,047,867 $1,029,382

See accompanying notes - 5 -
NATURE OF OPERATIONS

Life Sciences Ontario (the "Organization" or "LSO") was incorporated on December 13, 1989 under the provisions of the Canada Corporations Act and commenced operations shortly thereafter. The Organization is a not-for-profit corporation and is therefore exempt from income taxes.

The Organization represents and promotes Ontario’s vibrant and diverse life sciences sector. The Organization collaborates with governments, academia, industry and other life science organizations in Ontario, across Canada, and globally to promote and encourage commercial success throughout this diverse sector.

1. SIGNIFICANT ACCOUNTING POLICIES

These financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations and include the following significant accounting policies:

a) Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions based on currently available information. Such estimates and assumptions affect the reported amounts of assets and liabilities as at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from the estimates used.

Significant estimates include the estimated useful life of capital assets.

b) Cash and Cash Equivalents

Cash and cash equivalents consist of cash held in a bank account and a cashable GIC.

c) Capital Assets

Capital assets are recorded at cost. Amortization is being provided over the estimated useful life of the assets using the following annual rates and method:

<table>
<thead>
<tr>
<th>Asset Type</th>
<th>Rate</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computer</td>
<td>30%</td>
<td>declining balance</td>
</tr>
<tr>
<td>Furniture and fixtures</td>
<td>20%</td>
<td>declining balance</td>
</tr>
</tbody>
</table>
1. SIGNIFICANT ACCOUNTING POLICIES - Continued

d) Revenue Recognition

Special projects and events revenue consists of funding to undertake specific projects and events. Special projects and events revenue is recognized as expenses are incurred. Membership fees, sponsorships, events and meetings and education programs are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. Fees and sponsorships received pertaining to the subsequent period are deferred and recognized as revenue in the appropriate period. Government assistance is recognized when received and the underlying conditions for recognition of revenue have been fulfilled.

e) Financial Instruments

Measurement of Financial Instruments
The Organization initially measures its financial assets and liabilities originated or exchanged in arm’s length transactions at fair value and subsequently measures all its financial assets and financial liabilities at amortized cost.

Financial assets subsequently measured at amortized cost include cash and cash equivalents and accounts receivable. Financial liabilities subsequently measured at amortized cost include accounts payable and accrued liabilities and the CEBA loan.

The Organization has no financial assets measured at fair value and has not elected to carry any financial asset or liability at fair value.

Impairment
Financial assets measured at amortized cost are tested for impairment when events or circumstances indicate possible impairment. Write-downs, if any, are recognized in the excess of revenues over expenses and may be subsequently reversed to the extent that the net effect after the reversals is the same as if there had been no write-down. There are no impairment indicators in the current year.
2. CAPITAL ASSETS

Capital assets consist of the following:

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th></th>
<th>2021</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost</td>
<td>Accumulated Amortization</td>
<td>Net Book Value</td>
<td>Net Book Value</td>
</tr>
<tr>
<td>Computer</td>
<td>$14,415</td>
<td>$11,453</td>
<td>$2,962</td>
<td>$2,237</td>
</tr>
<tr>
<td>Furniture and fixtures</td>
<td>3,151</td>
<td>1,989</td>
<td>1,162</td>
<td>1,452</td>
</tr>
<tr>
<td></td>
<td>$17,566</td>
<td>$13,442</td>
<td>$4,124</td>
<td>$3,689</td>
</tr>
</tbody>
</table>

3. DEFERRED REVENUE

Deferred revenue consists of the following:

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special projects</td>
<td>$122,452</td>
<td>$267,255</td>
</tr>
<tr>
<td>Membership and general sponsorship</td>
<td>88,525</td>
<td>63,500</td>
</tr>
<tr>
<td>Education programs</td>
<td>12,750</td>
<td>-</td>
</tr>
<tr>
<td>Events and meetings</td>
<td>8,200</td>
<td>1,300</td>
</tr>
<tr>
<td></td>
<td>$231,927</td>
<td>$332,055</td>
</tr>
</tbody>
</table>

4. CEBA LOAN PAYABLE

The Organization received access to a $60,000 Canada Emergency Business Account (CEBA) loan as part of the Federal government’s response to COVID-19. The loan is non-interest bearing and is due December 31, 2023. $20,000 is forgivable if the $40,000 is repaid on or before December 31, 2023. The forgivable portion has been included in government assistance revenue in the prior years.

5. COMMITMENT

The Organization did not renew its lease agreement for its premises which expired on October 31, 2022. The Organization makes payments on a month-to-month basis of $3,100 excluding HST.
6. **FINANCIAL INSTRUMENTS**

   **Risks and Concentrations**

   The Organization is exposed to various risks through its financial instruments. The following analysis provides a summary of the Organization’s exposure to and concentrations of risk at December 31, 2022:

   a) **Credit Risk**

   Credit risk is the risk that one party to a financial instrument will cause loss for the other party by failing to discharge an obligation. The Organization’s main credit risks relate to its accounts receivable. The Organization provides credit to its members and clients in the normal course of operations. Actual exposure to credit losses has been minimal in prior years. There is no allowance for doubtful accounts. There has been no change in the assessment of credit risk from the prior year.

   b) **Liquidity Risk**

   Liquidity risk is the risk that the Organization will encounter difficulty in meeting obligations associated with financial liabilities. The Organization is exposed to this risk mainly with respect to its accounts payable and accrued liabilities and the CEBA loan. The Organization expects to meet its obligations by managing its working capital and by generating sufficient cash flows from operations. There has been no change in the assessment of liquidity risk from the prior year.

   c) **Market Risk**

   Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and price risk. The Organization is not exposed to significant market risk.

7. **COVID-19**

   During the year, the Organization recognized $Nil (2021 - $107,214) of government assistance as part of the federal government’s COVID-19 emergency wage subsidy program and an additional $Nil (2021- $10,000) for the forgivable portion of the CEBA loan.
To become a member or for information about LSO’s activities, please contact:

**LSO Office**
350 Bay Street, Suite 700
Toronto, ON M5H 2S6

admin@lifesciencesontario.ca

[www.lifesciencesontario.ca](http://www.lifesciencesontario.ca)
@LifeSciencesON